Abstract
This article describes a novel method merging the cloning of viral vector producer cells with vector titer screening, allowing for screening 200–500 clones in 2 weeks. It makes use of a GFP separated into two fragments, S10 and S11 (Split GFP), fluorescing only upon transcomplementation. Producer cells carrying a S11 viral transgene are cloned in 96-well plates and co-cultured with target cells stably expressing S10. During the period of clone expansion, S11 viruses infect S10 target cells reconstituting the GFP signal. Transcomplemented fluorescence data provide direct estimation of the clone’s productivity and can be analyzed in terms of density distribution, offering valuable information on the average productivity of the cell population and allowing the identification of high-producing clones. The method was validated by establishing a retrovirus producer from a nude cell line, in <3 months, inserting three vector constructs without clone selection or screening in between. Clones producing up to 108 infectious particles per ml were obtained, delivering optimal ratios of infectious-to-total particles (1 to 5). The method was additionally used to evaluate the production performance of HEK 293 and HEK 293T cell lines demonstrating that the latter sustains increased titers. Finally, it was used to study genetic manipulation of glutathione metabolism in retrovirus production showing that changing cell metabolism steers higher vector expression with titer increases of more than one order of magnitude.This method is a valuable tool not only for cell line development but also for genetic manipulation of viral vector and/or producer cells contributing to advancing the field of viral gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Edelstine M . The Journal of Gene Medicine Clinical Trial Site. http://www.wiley.com/legacy/wileychi/genmed/clinical.
Moran N . First gene therapy nears landmark European market authorization. Nat Biotechnol 2012; 30: 807–809.
Sheridan C . Gene therapy finds its niche. Nat Biotechnol 2011; 29: 121–128.
Ikeda Y, Takeuchi Y, Martin F, Cosset FL, Mitrophanous K, Collins M . Continuous high-titer HIV-1 vector production. Nat Biotechnol 2003; 21: 569–572.
Stornaiuolo A, Piovani BM, Bossi S, Zucchelli E, Corna S, Salvatori F et al. RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy. Hum Gene Ther Methods 2013; 24: 228–240.
Coroadinha AS, Gama-Norton L, Amaral AI, Hauser H, Alves PM, Cruz PE . Production of retroviral vectors: review. Curr Gene Ther 2010; 10: 456–473.
Schweizer M, Merten OW . Large-scale production means for the manufacturing of lentiviral vectors. Curr Gene Ther 2010; 10: 474–486.
Seymour LW, Thrasher AJ . Gene therapy matures in the clinic. Nat Biotechnol 2012; 30: 588–593.
Carrondo M, Panet A, Wirth D, Coroadinha AS, Cruz P, Falk H et al. Integrated strategy for the production of therapeutic retroviral vectors. Hum Gene Ther 2011; 22: 370–379.
Coroadinha AS, Schucht R, Gama-Norton L, Wirth D, Hauser H, Carrondo MJ . The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange. J Biotechnol 2006; 124: 457–468.
Gama-Norton L, Herrmann S, Schucht R, Coroadinha AS, Low R, Alves PM et al. Retroviral vector performance in defined chromosomal Loci of modular packaging cell lines. Hum Gene Ther 2010; 21: 979–991.
Hennig K, Raasch L, Kolbe C, Weidner S, Leisegang M, Uckert W et al. HEK293-based production platform for gamma-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA. Hum Gene Ther Clin Dev 2014; 25: 218–228.
Loew R, Meyer Y, Kuehlcke K, Gama-Norton L, Wirth D, Hauser H et al. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration. Gene Ther 2010; 17: 272–280.
Schucht R, Coroadinha AS, Zanta-Boussif MA, Verhoeyen E, Carrondo MJ, Hauser H et al. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors. Mol Ther 2006; 14: 285–292.
Cabantous S, Terwilliger TC, Waldo GS . Protein tagging and detection with engineered self-assembling fragments of green fluorescent protein. Nat Biotechnol 2005; 23: 102–107.
Green BJ, Rasko JE . Rapid screening for high-titer retroviral packaging cell lines using an in situ fluorescence assay. Hum Gene Ther 2002; 13: 1005–1013.
Ou W, Marino MP, Lu C, Reiser J . Rapid titration of retroviral vectors using a beta-lactamase protein fragment complementation assay. Gene Ther 2012; 20: 43–50.
Carrondo MJ, Merten OW, Haury M, Alves PM, Coroadinha AS . Impact of retroviral vector components stoichiometry on packaging cell lines: effects on productivity and vector quality. Hum Gene Ther 2008; 19: 199–210.
Gama-Norton L, Botezatu L, Herrmann S, Schweizer M, Alves PM, Hauser H et al. Lentivirus production is influenced by SV40 large T-antigen and chromosomal integration of the vector in HEK293 cells. Hum Gene Ther 2011; 22: 1269–1279.
Rodrigues AF, Carrondo MJ, Alves PM, Coroadinha AS . Cellular targets for improved manufacturing of virus-based biopharmaceuticals in animal cells. Trends Biotechnol 2014; 32: 602–607.
Rodrigues AF, Formas-Oliveiras AS, Bandeira VS, Alves PM, Hu WS, Coroadinha AS . Metabolic pathways recruited in the production of a recombinant enveloped virus: mining targets for process and cell engineering. Metab Eng 2013; 20: 131–145.
Schambach A, Galla M, Maetzig T, Loew R, Baum C . Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 2007; 15: 1167–1173.
Vu HN, Ramsey JD, Pack DW . Engineering of a stable retroviral gene delivery vector by directed evolution. Mol Ther 2008; 16: 308–314.
DuBridge R, Tang P, Hsia H, Leong P, Miller J, Calos M . Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987; 7: 379–387.
Rio D, Clark S, Tjian R . A mammalian host-vector system that regulates expression and amplification of transfected genes by temperature induction. Science 1985; 227: 23–28.
Merten OW, Charrier S, Laroudie N, Fauchille S, Dugue C, Jenny C et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 2011; 22: 343–356.
Verhoeyen E, Hauser H, Wirth D . Evaluation of retroviral vector design in defined chromosomal loci by Flp-mediated cassette replacement. Hum Gene Ther 2001; 12: 933–944.
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463–8471.
Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK . High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430–7436.
Bodin L, Beaune PH, Loriot MA . Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. J Biomed Biotechnol 2005; 2005: 248–253.
Rodrigues AF, Amaral AI, Verissimo V, Alves PM, Coroadinha AS . Adaptation of retrovirus producer cells to serum deprivation: Implications in lipid biosynthesis and vector production. Biotechnol Bioeng 2012; 109: 1269–1279.
Rodrigues AF, Carmo M, Alves PM, Coroadinha AS . Retroviral vector production under serum deprivation: the role of lipids. Biotechnol Bioeng 2009; 104: 1171–1181.
Carmo M, Peixoto C, Coroadinha AS, Alves PM, Cruz PE, Carrondo MJ . Quantitation of MLV-based retroviral vectors using real-time RT-PCR. J Virol Methods 2004; 119: 115–119.
Wand MP, Jones MC . Kernel Smoothing. Chapman and Hall/CRC: Boca Raton, FL, USA: Boca Raton, FL, USA, 1995.
Acknowledgements
We acknowledge Drs Catarina Duarte and Teresa Serra from Nutraceuticals and Delivery Laboratory, iBET, for access to the spectrofluorometer. We also acknowledge Fundação para a Ciência e a Tecnologia (FCT), Portugal, for financial support PTDC/EBB-BIO/118621/2010 and PTDC/EBB-BIO/118615/2010. ASF-O, MRG and HAT received PhD grants from FCT (SFRH/BD/97002/2013, SFRH/BD/90685/2012 and SFRH/BD/79022/2011, respectively).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Gene Therapy website
Supplementary information
Rights and permissions
About this article
Cite this article
Rodrigues, A., Formas-Oliveira, A., Guerreiro, M. et al. Single-step cloning-screening method: a new tool for developing and studying high-titer viral vector producer cells. Gene Ther 22, 685–695 (2015). https://doi.org/10.1038/gt.2015.44
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2015.44
This article is cited by
-
LentiPro26: novel stable cell lines for constitutive lentiviral vector production
Scientific Reports (2018)